Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals.

ABSTRACT: We recently reported using non-targeted metabolic profiling that serum indolepropionic acid (IPA), a microbial metabolite of tryptophan, was associated with a lower likelihood of developing type 2 diabetes (T2D). In the present study, we established a targeted quantitative method using liquid chromatography with mass spectrometric detection (HPLC-QQQ-MS/MS) and measured the serum concentrations of IPA in all the participants from the Finnish Diabetes Prevention Study (DPS), who had fasting serum samples available from the 1-year study follow-up (n?=?209 lifestyle intervention and n?=?206 control group). Higher IPA at 1-year study was inversely associated with the incidence of T2D (OR [CI]: 0.86 [0.73-0.99], P?=?0.04) and tended to be directly associated with insulin secretion (??=?0.10, P?=?0.06) during the mean 7-year follow-up. Moreover, IPA correlated positively with dietary fiber intake (g/day: r?=?0.24, P?=?1?×?10-6) and negatively with hsCRP concentrations at both sampling (r?=?-?0.22, P?=?0.0001) and study follow-up (??=?-?0.19, P?=?0.001). Thus, we suggest that the putative effect of IPA on lowering T2D risk might be mediated by the interplay between dietary fiber intake and inflammation or by direct effect of IPA on ?-cell function.

SUBMITTER: Tuomainen M 

PROVIDER: S-EPMC5968030 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature